Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Recurrent Brain Neoplasm: early-phase trial registry

1 of 10 indexed Recurrent Brain Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 1 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Recurrent Brain Neoplasm: 10 US clinical trials tracked, 1 recruiting.

Recurrent Brain Neoplasm is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.

Enrollment posture brief

Registry condition recurrent-brain-neoplasm

OPEN 1 | RECR 10% | LATE 0 | EARLY 5 | RANK #1724 | SPON 4

Nearest open-share peer: Angina Pectoris (10% recruiting · 10 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Recurrent Brain Neoplasm (th…10%
Open-enrollment share among volume-matched conditions near Recurrent Brain Neoplasm

Recurrent Brain Neoplasm lists 1 open slots (10% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Brain Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Brain Neoplasm is recruiting below its size-band peers.

    1 of 10 indexed trials (10%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Recurrent Brain Neoplasm research.

    M.D. Anderson Cancer Center accounts for 4 of 10 trials (40%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Recurrent Brain Neoplasm trials plan to enrol fewer than 100 people.

    Median target enrolment is 54 among the 10 trials that report a genuine target (sentinel values excluded). 9 of those (90%) plan for fewer than 100 participants.

  4. Recurrent Brain Neoplasm research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 21

Open and recent trials

10 total, page 1 of 1

RECRUITING NA 75 participants

Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

M.D. Anderson Cancer Center

NCT02754544

ACTIVE NOT RECRUITING Phase 1 71 participants

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

NCT02359565

ACTIVE NOT RECRUITING NA 45 participants

Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy

Children's Oncology Group

NCT01503086

ACTIVE NOT RECRUITING NA 40 participants

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

M.D. Anderson Cancer Center

NCT02698254

ACTIVE NOT RECRUITING Phase 1 14 participants

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

M.D. Anderson Cancer Center

NCT02389309

COMPLETED Phase 2 137 participants

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

National Cancer Institute (NCI)

NCT01609790

COMPLETED Phase 1 59 participants

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Children's Oncology Group

NCT02323880

COMPLETED 54 participants

Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery

Mayo Clinic

NCT03071913

COMPLETED NA 10 participants

Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

Jonsson Comprehensive Cancer Center

NCT02575027

COMPLETED Phase 1 8 participants

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

M.D. Anderson Cancer Center

NCT01904123

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1

Named interventions

Most-linked intervention names on Recurrent Brain Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
4 trials
Pharmacological Study Other
3 trials
Bevacizumab Biological
2 trials
Questionnaire Administration Other
2 trials
Quality-of-Life Assessment Other
2 trials
Biospecimen Collection Procedure
2 trials
Trebananib Biological
1 trials
Psychosocial Assessment and Care Procedure
1 trials

US sites by state

Facility locations filed on Recurrent Brain Neoplasm trials. A trial with sites in several states counts in each.

Texas 5 trials
Colorado 4 trials
California 4 trials
Tennessee 3 trials
Pennsylvania 3 trials
New York 3 trials
Georgia 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recurrent Brain Neoplasm page

10 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Brain Neoplasm condition card totals 10 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.